Which has preferable valuation & earnings, AUNA or XGN?

Auna has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Auna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Auna $1.23B 0.31 $27.39M $0.26 19.69 Exagen $66.57M 1.60 -$19.95M -$0.89 N/A

Is AUNA or XGN more profitable?

Auna has a net margin of 1.53% compared to Exagen's net margin of -29.49%. Auna's return on equity of 16.25% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Auna 1.53% 16.25% 4.03% Exagen -29.49% -94.37% -28.96%

Which has preferable earnings & valuation, SBC or XGN?

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SBC Medical Group $173.61M 1.83 $50.99M $0.39 7.94 Exagen $66.57M 1.60 -$19.95M -$0.89 N/A

Is SBC or XGN more profitable?

SBC Medical Group has a net margin of 24.09% compared to Exagen's net margin of -29.49%. SBC Medical Group's return on equity of 15.90% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets SBC Medical Group 24.09% 15.90% 11.61% Exagen -29.49% -94.37% -28.96%

Which has stronger earnings & valuation, LFMD or XGN?

LifeMD has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 1.04 $14.35M $0.05 83.50 Exagen $66.57M 1.60 -$19.95M -$0.89 N/A

Is LFMD or XGN more profitable?

LifeMD has a net margin of 2.37% compared to Exagen's net margin of -29.49%. Exagen's return on equity of -94.37% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Exagen -29.49% -94.37% -28.96%

Which has stronger valuation and earnings, XGN or BDSX?

Exagen has higher earnings, but lower revenue than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.60 -$19.95M -$0.89 N/A Biodesix $88.50M 2.34 -$35.26M -$4.06 N/A

Is XGN or BDSX more profitable?

Exagen has a net margin of -29.49% compared to Biodesix's net margin of -33.26%. Exagen's return on equity of -94.37% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -29.49% -94.37% -28.96% Biodesix -33.26% -2,101.40% -35.65%

Exagen (XGN) Competitors

$4.40 +0.16 (+3.65%)

As of 03:57 PM Eastern

Compare

XGN vs. AUNA, SBC, AIRS, LFMD, and BDSX

Should you buy Exagen stock or one of its competitors? MarketBeat compares Exagen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exagen include Auna (AUNA), SBC Medical Group (SBC), AirSculpt Technologies (AIRS), LifeMD (LFMD), and Biodesix (BDSX). These companies are all part of the "healthcare" industry.

How does Exagen compare to Auna?

Auna (NYSE:AUNA) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Auna has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Exagen has a beta of 2.02, indicating that its share price is 102% more volatile than the broader market.

75.3% of Exagen shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Auna has a net margin of 1.53% compared to Exagen's net margin of -29.49%. Auna's return on equity of 16.25% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Auna	1.53%	16.25%	4.03%
Exagen	-29.49%	-94.37%	-28.96%

Auna has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than Auna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Auna	$1.23B	0.31	$27.39M	$0.26	19.69
Exagen	$66.57M	1.60	-$19.95M	-$0.89	N/A

Auna presently has a consensus price target of $6.97, indicating a potential upside of 36.07%. Exagen has a consensus price target of $9.11, indicating a potential upside of 106.84%. Given Exagen's stronger consensus rating and higher probable upside, analysts clearly believe Exagen is more favorable than Auna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Auna	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Auna had 1 more articles in the media than Exagen. MarketBeat recorded 2 mentions for Auna and 1 mentions for Exagen. Exagen's average media sentiment score of 1.87 beat Auna's score of 0.34 indicating that Exagen is being referred to more favorably in the news media.

Company	Overall Sentiment
Auna	Neutral
Exagen	Very Positive

Summary

Auna and Exagen tied by winning 8 of the 16 factors compared between the two stocks.

How does Exagen compare to SBC Medical Group?

SBC Medical Group (NASDAQ:SBC) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

60.8% of SBC Medical Group shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 81.7% of SBC Medical Group shares are held by insiders. Comparatively, 10.4% of Exagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, SBC Medical Group had 3 more articles in the media than Exagen. MarketBeat recorded 4 mentions for SBC Medical Group and 1 mentions for Exagen. Exagen's average media sentiment score of 1.87 beat SBC Medical Group's score of 0.76 indicating that Exagen is being referred to more favorably in the news media.

Company	Overall Sentiment
SBC Medical Group	Positive
Exagen	Very Positive

SBC Medical Group has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SBC Medical Group	$173.61M	1.83	$50.99M	$0.39	7.94
Exagen	$66.57M	1.60	-$19.95M	-$0.89	N/A

SBC Medical Group currently has a consensus price target of $8.50, indicating a potential upside of 174.64%. Exagen has a consensus price target of $9.11, indicating a potential upside of 106.84%. Given SBC Medical Group's higher probable upside, research analysts plainly believe SBC Medical Group is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

SBC Medical Group has a net margin of 24.09% compared to Exagen's net margin of -29.49%. SBC Medical Group's return on equity of 15.90% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SBC Medical Group	24.09%	15.90%	11.61%
Exagen	-29.49%	-94.37%	-28.96%

SBC Medical Group has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Exagen has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

Summary

SBC Medical Group beats Exagen on 11 of the 17 factors compared between the two stocks.

How does Exagen compare to AirSculpt Technologies?

Exagen (NASDAQ:XGN) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

75.3% of Exagen shares are held by institutional investors. Comparatively, 91.5% of AirSculpt Technologies shares are held by institutional investors. 10.4% of Exagen shares are held by insiders. Comparatively, 44.6% of AirSculpt Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Exagen currently has a consensus target price of $9.11, suggesting a potential upside of 106.84%. AirSculpt Technologies has a consensus target price of $4.50, suggesting a potential upside of 1.42%. Given Exagen's stronger consensus rating and higher probable upside, equities analysts plainly believe Exagen is more favorable than AirSculpt Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

AirSculpt Technologies has higher revenue and earnings than Exagen. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.60	-$19.95M	-$0.89	N/A
AirSculpt Technologies	$151.82M	2.06	-$11.67M	-$0.17	N/A

AirSculpt Technologies has a net margin of -7.39% compared to Exagen's net margin of -29.49%. AirSculpt Technologies' return on equity of -4.98% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
AirSculpt Technologies	-7.39%	-4.98%	-2.36%

Exagen has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, AirSculpt Technologies has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market.

In the previous week, Exagen and Exagen both had 1 articles in the media. Exagen's average media sentiment score of 1.87 equaled AirSculpt Technologies'average media sentiment score.

Company	Overall Sentiment
Exagen	Very Positive
AirSculpt Technologies	Very Positive

Summary

AirSculpt Technologies beats Exagen on 10 of the 15 factors compared between the two stocks.

How does Exagen compare to LifeMD?

LifeMD (NASDAQ:LFMD) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

In the previous week, LifeMD had 1 more articles in the media than Exagen. MarketBeat recorded 2 mentions for LifeMD and 1 mentions for Exagen. Exagen's average media sentiment score of 1.87 beat LifeMD's score of 1.49 indicating that Exagen is being referred to more favorably in the news media.

Company	Overall Sentiment
LifeMD	Positive
Exagen	Very Positive

LifeMD has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.04	$14.35M	$0.05	83.50
Exagen	$66.57M	1.60	-$19.95M	-$0.89	N/A

LifeMD has a net margin of 2.37% compared to Exagen's net margin of -29.49%. Exagen's return on equity of -94.37% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Exagen	-29.49%	-94.37%	-28.96%

LifeMD currently has a consensus price target of $9.14, indicating a potential upside of 118.99%. Exagen has a consensus price target of $9.11, indicating a potential upside of 106.84%. Given LifeMD's higher possible upside, analysts clearly believe LifeMD is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

LifeMD has a beta of 1.99, indicating that its stock price is 99% more volatile than the broader market. Comparatively, Exagen has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

35.5% of LifeMD shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 17.2% of LifeMD shares are held by insiders. Comparatively, 10.4% of Exagen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

LifeMD beats Exagen on 9 of the 16 factors compared between the two stocks.

How does Exagen compare to Biodesix?

Exagen (NASDAQ:XGN) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Exagen has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

75.3% of Exagen shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 10.4% of Exagen shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Exagen has a net margin of -29.49% compared to Biodesix's net margin of -33.26%. Exagen's return on equity of -94.37% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
Biodesix	-33.26%	-2,101.40%	-35.65%

Exagen has higher earnings, but lower revenue than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.60	-$19.95M	-$0.89	N/A
Biodesix	$88.50M	2.34	-$35.26M	-$4.06	N/A

In the previous week, Exagen and Exagen both had 1 articles in the media. Exagen's average media sentiment score of 1.87 equaled Biodesix'saverage media sentiment score.

Company	Overall Sentiment
Exagen	Very Positive
Biodesix	Very Positive

Exagen presently has a consensus target price of $9.11, indicating a potential upside of 106.84%. Biodesix has a consensus target price of $28.33, indicating a potential upside of 41.70%. Given Exagen's stronger consensus rating and higher possible upside, research analysts clearly believe Exagen is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Exagen beats Biodesix on 11 of the 14 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XGN vs. The Competition

Export

Metric	Exagen	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$105.97M	$8.63B	$6.85B	$12.28B
Dividend Yield	N/A	2.56%	2.68%	8.87%
P/E Ratio	-4.93	16.01	27.24	23.92
Price / Sales	1.60	6.91	581.21	112.37
Price / Cash	N/A	18.07	49.25	59.89
Price / Book	5.72	3.29	10.72	6.19
Net Income	-$19.95M	$228.19M	$3.59B	$331.73M
7 Day Performance	-1.01%	-2.35%	-2.14%	-2.23%
1 Month Performance	3.65%	-0.51%	2.14%	-1.57%
1 Year Performance	-38.65%	-0.93%	24.72%	16.99%

Exagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XGN Exagen	3.75 of 5 stars	$4.41 +3.6%	$9.11 +106.8%	-39.3%	$105.97M	$66.57M	N/A	220
AUNA Auna	4.8813 of 5 stars	$5.08 -3.3%	$6.97 +37.3%	-19.3%	$388.57M	$1.23B	19.52	15,254	News Coverage
SBC SBC Medical Group	3.8048 of 5 stars	$3.09 -0.3%	$8.50 +175.1%	-39.5%	$317.99M	$173.61M	7.92	N/A
AIRS AirSculpt Technologies	1.2285 of 5 stars	$4.20 flat	$4.50 +7.1%	-23.0%	$296.29M	$151.82M	N/A	240	Positive News
LFMD LifeMD	3.0055 of 5 stars	$4.51 -5.3%	$9.14 +102.7%	-60.2%	$230.21M	$194.05M	90.22	230	News Coverage Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XGN) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exagen (XGN) Competitors